EIGR - Eiger BioPharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
51,011
37,091
29,519
33,014
21,959
Selling General and Administrative
16,007
13,956
12,001
13,106
12,435
Total Operating Expenses
67,018
51,047
41,520
46,120
34,394
Operating Income or Loss
-67,018
-51,047
-41,520
-46,120
-34,394
Interest Expense
3,070
2,329
1,524
690
2,302
Total Other Income/Expenses Net
0
-12
186
-277
-7,782
Income Before Tax
-68,361
-52,391
-42,448
-47,087
-44,413
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-68,361
-52,391
-42,448
-47,087
-44,413
Net Income
-68,361
-52,391
-42,448
-47,087
-44,413
Net Income available to common shareholders
-68,361
-52,391
-42,448
-47,087
-44,413
Reported EPS
Basic
-
-3.82
-4.86
-7.84
-27.93
Diluted
-
-3.82
-4.86
-7.84
-27.93
Weighted average shares outstanding
Basic
-
13,711
8,728
6,007
1,590
Diluted
-
13,711
8,728
6,007
1,590
EBITDA
-
-50,062
-40,924
-46,397
-41,607